Trial Profile

A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ensifentrine (Primary)
Indications Chronic obstructive pulmonary disease
Focus Pharmacokinetics; Therapeutic Use
Sponsors Verona Pharma

Most Recent Events

20 Jul 2022 According to ClinicalTrials.gov record (NCT04091360), time frame for primary end point has been increased from 12hours to 1 day.
13 Oct 2021 According to a Verona Pharma media release, data from this trial will be presented at CHEST Annual Meeting ("CHEST") 2021 .
25 Feb 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com